TNFSF4 antibody (PE)

Catalog No. ABIN2663215

Product Details anti-TNFSF4 Antibody (PE)

Target: TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (TNFSF4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFSF4 antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: 11C3-1

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TNFSF4

Target: TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (TNFSF4))

Alternative Name: CD252 (TNFSF4 Products)

Background: OX40 ligand (OX40L) is a 35 kD type II transmembrane protein which belongs to TNF superfamily, also known as gp34, CD252, CD134L or TNFSF4. The OX40 ligand is expressed on activated B cells, activated endothelial cells, mature dendritic cells, activated CTLs, activated mast cells, and airway smooth muscle cells. OX40 ligand interacts with OX40 antigen (CD134) expressed predominantly on activated T cells to regulate T cell proliferation and differentiation, and to enhance immunoglobulin secretion by activated B cells.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation, Cancer Immune Checkpoints